Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors

Giulio Poli, Margherita Lapillo, Carlotta Granchi, Jessica Caciolla, Nayla Mouawad, Isabella Caligiuri, Flavio Rizzolio, Thierry Langer, Filippo Minutolo, Tiziano TuccinardiJournal of Enzyme Inhibition and Medicinal Chemistry 2018 · DOI

TL;DR

Researchers have computationally investigated the binding of a promising Fyn kinase inhibitor (VS6) to its target, confirming its binding mode. This led to the design and synthesis of a new derivative that is six times more potent, offering a promising avenue for developing new cancer and neurodegenerative disease therapies.

What Problem Does This Paper Address?

Fyn kinase is a crucial player in various cellular processes, and its dysregulation is implicated in numerous human diseases, including several types of cancer (prostate, breast, ovarian, glioblastoma, neuroblastoma) and neurodegenerative disorders like Alzheimer's and Parkinson's. Consequently, developing selective Fyn kinase inhibitors is a significant therapeutic goal. While some Fyn inhibitors exist, there's a need for more potent and selective compounds, especially those that can overcome resistance mechanisms in cancer treatment. This paper addresses the challenge of optimizing existing Fyn inhibitors by understanding their binding mechanisms and rationally designing improved versions.

Methods

The study employed a multi-pronged computational and experimental approach:

  • Consensus Docking: This technique combines the results from multiple docking algorithms (AUTODOCK, DOCK, FRED, GOLD, GLIDE, PLANTS) to predict the most likely binding pose of a ligand within a protein's active site. This approach aims to improve reliability over single docking methods.
  • Molecular Dynamics (MD) Simulations: Long-term simulations (100 ns) were used to observe the dynamic behavior of the Fyn kinase-ligand complex, allowing for the assessment of the stability of predicted binding poses and interactions.
  • Binding Energy Evaluation (MM-PBSA): The Molecular Mechanics-Poisson-Boltzmann Surface Area (MM-PBSA) method was used to estimate the binding free energy of the ligand-protein complexes, providing a quantitative measure of binding affinity.
  • Fyn Kinase Assays: In vitro biochemical assays were performed to measure the inhibitory potency (IC50 values) of synthesized compounds against Fyn kinase.
  • Cell Viability Assays: Assays using human cancer cell lines (MDA-MB-231 and A549) were conducted to evaluate the antiproliferative effects of the most promising compounds.

Datasets

Not explicitly discussed as datasets in the paper. The study utilized the crystal structure of human Fyn kinase (PDB code 2DQ7) as the target for computational modeling. The compounds tested were either synthesized in-house or purchased from commercial suppliers.

Key Insights and Ideas

  • Confirmation of VS6 Binding Mode: The consensus docking and MD simulations provided strong evidence for the hypothesized binding mode of the initial hit compound, VS6, within the Fyn kinase active site. This validation is crucial for guiding further optimization efforts.
  • Importance of T342 Interaction: The study highlighted the role of a hydrogen bond between the ligand and the hydroxyl group of residue T342. Replacing the benzodioxole ring of VS6 with a cyclohexyl group (compound 3) significantly enhanced binding and potency, suggesting that this modification favorably positions the ligand for this interaction.
  • Scaffold Robustness: Modifying the substituent at the 6-position of the triazinone core (where the methyl group of VS6 was located) with a p-fluorobenzyl group (compound 1) did not significantly alter inhibitory activity, indicating that this position is less critical for binding and can be a site for further diversification.
  • Structure-Activity Relationship (SAR) Insights: The comparison between VS6, compound 2 (phenyl replacement), and compound 3 (cyclohexyl replacement) provided valuable SAR insights, demonstrating how structural modifications impact Fyn inhibition. Compound 3's improved activity was attributed to a more favorable interaction with T342 and potentially better overall binding.

Key Results

  • Compound VS6: Exhibited a micromolar inhibition of Fyn kinase with an IC50 of 4.8 μM.
  • Compound 1: A derivative with a p-fluorobenzyl group at the 6-position, showed an IC50 similar to VS6, suggesting this modification did not significantly impact potency.
  • Compound 3: A derivative with a cyclohexyl group at the 6-position, demonstrated a significant improvement in potency, with an IC50 of 0.76 μM, representing a six-fold increase compared to VS6.
  • Compound 2: A derivative with a phenyl group at the 6-position, showed very low potency (IC50 > 100 μM).
  • Cell Viability: Compound 3 exhibited antiproliferative activity against human breast (MDA-MB-231) and lung (A549) cancer cell lines, with IC50 values ranging from 34.8 to 101.0 μM, which were lower than those of VS6.

Limitations and Future Work

  • Limitations:
    • The study focused on a specific scaffold (3-amino-1,2,4-triazin-5(2H)-one) and its derivatives.
  • While compound 3 showed improved potency, its IC50 values in cell-based assays are still in the micromolar range, suggesting room for further optimization.
  • The paper acknowledges that potent Fyn inhibitors with high selectivity over other SFKs are still missing.
  • Future Work:
    • Further structural optimization of compound 3 to achieve even higher potency and selectivity.
  • Investigating the selectivity profile of compound 3 against other kinases, particularly other Src family kinases.
  • Exploring the therapeutic potential of compound 3 in preclinical models of cancer and neurodegenerative diseases.
  • Expanding the exploration of the 3-amino-1,2,4-triazin-5(2H)-one scaffold for the development of novel Fyn inhibitors.

Summary updated

Abstract

Fyn tyrosine kinase inhibitors are considered potential therapeutic agents for a variety of human cancers. Furthermore, the involvement of Fyn kinase in signalling pathways that lead to severe pathologies, such as Alzheimer's and Parkinson's diseases, has also been demonstrated. In this study, starting from 3-(benzo[d][1,3]dioxol-5-ylamino)-6-methyl-1,2,4-triazin-5(2H)-one (VS6), a hit compound that showed a micromolar inhibition of Fyn (IC<sub>50</sub> = 4.8 μM), we computationally investigated the binding interactions of the 3-amino-1,2,4-triazin-5(2H)-one scaffold and started a preliminary hit to lead optimisation. This analysis led us to confirm the hypothesised binding mode of VS6 and to identify a new derivative that is about 6-fold more active than VS6 (compound 3, IC<sub>50</sub> = 0.76 μM).
BibTeX
@article{poli2018binding,
  author = {Giulio Poli and Margherita Lapillo and Carlotta Granchi and Jessica Caciolla and Nayla Mouawad and Isabella Caligiuri and Flavio Rizzolio and Thierry Langer and Filippo Minutolo and Tiziano Tuccinardi},
  title = {{Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2<i>H</i>)-one core for the development of new Fyn inhibitors}},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2018},
  doi = {10.1080/14756366.2018.1469017},
}
Figure